8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Mar 9, 2026·SEC
Lyell Immunopharma, Inc.(LYEL)Earnings, Financials & Key Ratios
LYEL•NASDAQ
$20.06
$468M mkt cap·Price updated May 7, 2026
AboutLyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Show more
- Revenue$36K-41.0%
- EBITDA-$192M+43.3%
- Net Income-$274M+20.0%
- EPS (Diluted)-16.06-1126.0%
- Gross Margin-31952.78%-32052.8%
- EBITDA Margin-533986.11%+3.9%
- Operating Margin-566038.89%+3.8%
- Net Margin-762355.56%-35.6%
- ROE-86.98%-31.6%
- ROIC-53.99%+8.8%
- Debt/Equity0.17+9.7%
LYEL Key Insights
Lyell Immunopharma, Inc. (LYEL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 65.9% over 5 years
- ✗Shares diluted 30.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LYEL Price & Volume
Lyell Immunopharma, Inc. (LYEL) stock price & volume — 10-year historical chart
Loading chart...
LYEL Growth Metrics
Lyell Immunopharma, Inc. (LYEL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-65.85%
3 Years-92.48%
TTM-52.31%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.34%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-919.69%
Return on Capital
10 Years-34.2%
5 Years-37.97%
3 Years-49.61%
Last Year-56%
LYEL Recent Earnings
Lyell Immunopharma, Inc. (LYEL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (75%)
Q2 2026Latest
May 6, 2026EPS
$1.10
Est $2.78
+60.4%
Revenue
$2,000
Est $3,000
-33.3%
Q2 2026
Mar 12, 2026EPS
$7.68
Est $2.15
-257.2%
Revenue
$6,000
Est $15,250
-60.7%
Q4 2025
Nov 12, 2025EPS
$2.13
Est $2.81
+24.2%
Revenue
$15,000
Q3 2025
Aug 12, 2025EPS
$2.89
Est $3.80
+23.9%
Revenue
$8,000
Est $4,000
+100.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $1.10vs $2.78+60.4% | $2,000vs $3,000-33.3% |
| Q2 2026 | Mar 12, 2026 | $7.68vs $2.15-257.2% | $6,000vs $15,250-60.7% |
| Q4 2025 | Nov 12, 2025 | $2.13vs $2.81+24.2% | $15,000 |
| Q3 2025 | Aug 12, 2025 | $2.89vs $3.80+23.9% | $8,000vs $4,000+100.0% |
Based on last 12 quarters of dataView full earnings history →
LYEL Peer Comparison
Lyell Immunopharma, Inc. (LYEL) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 ADCT | 478.24M | 3.76 | -3.36 | 14.85% | -173.02% | |||
 CABA | 409.05M | 4.00 | -2.44 | -121.73% | 0.24 | |||
 TGTX | 6.87B | 43.03 | 15.53 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ALKT | 1.87B | 17.43 | -37.89 | 32.89% | -10.55% | -13.96% | 0.98 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 |
Compare LYEL vs Peers
Lyell Immunopharma, Inc. (LYEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LYEL Income Statement
Lyell Immunopharma, Inc. (LYEL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 657K | 7.76M | 10.65M | 84.68M | 130K | 61K | 36K | 31K |
| Revenue Growth % | - | 1080.52% | 37.31% | 695.15% | -99.85% | -53.08% | -40.98% | -52.31% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 11.54M | 2.4M |
| COGS % of Revenue | - | - | - | - | - | - | 32052.78% | - |
| Gross Profit | 657K▲ 0% | 7.76M▲ 1080.5% | 10.65M▲ 37.3% | 84.68M▲ 695.1% | 130K▼ 99.8% | 61K▼ 53.1% | -11.5M▼ 18957.4% | -11.51M▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | -31952.78% | -37129.03% |
| Gross Profit Growth % | - | 1080.52% | 37.31% | 695.15% | -99.85% | -53.08% | -18957.38% | - |
| Operating Expenses | 102.75M | 219.69M | 225.43M | 271.74M | 247.14M | 358.82M | 192.27M | 190.99M |
| OpEx % of Revenue | 15638.66% | 2832.56% | 2116.68% | 320.89% | 190106.15% | 588222.95% | 534086.11% | - |
| Selling, General & Admin | 39.15M | 46.88M | 89.06M | 117.31M | 66.98M | 52.04M | 45.13M | 40.64M |
| SG&A % of Revenue | 5959.06% | 604.45% | 836.22% | 138.52% | 51525.38% | 85313.11% | 125375% | - |
| Research & Development | 63.59M | 182.24M | 138.69M | 159.19M | 182.94M | 171.6M | 158.68M | 151.83M |
| R&D % of Revenue | 9679.6% | 2349.7% | 1302.28% | 187.98% | 140726.92% | 281316.39% | 440763.89% | - |
| Other Operating Expenses | 0 | -9.43M | -2.32M | -4.75M | -2.79M | 135.17M | -11.54M | -1000K |
| Operating Income | -102.09M▲ 0% | -211.94M▼ 107.6% | -214.78M▼ 1.3% | -187.06M▲ 12.9% | -247.01M▼ 32.0% | -358.75M▼ 45.2% | -203.77M▲ 43.2% | -148.3M▲ 0% |
| Operating Margin % | -15538.66% | -2732.56% | -2016.68% | -220.89% | -190006.15% | -588122.95% | -566038.89% | -478396.77% |
| Operating Income Growth % | - | -107.6% | -1.34% | 12.91% | -32.05% | -45.24% | 43.2% | - |
| EBITDA | -100.83M | -207.64M | -201.15M | -169.04M | -226.76M | -339.12M | -192.24M | -140.21M |
| EBITDA Margin % | -15347.49% | -2677.19% | -1888.75% | -199.61% | -174429.23% | -555940.98% | -533986.11% | -452274.19% |
| EBITDA Growth % | - | -105.93% | 3.13% | 15.96% | -34.15% | -49.55% | 43.31% | 59.06% |
| D&A (Non-Cash Add-back) | 1.26M | 4.29M | 13.62M | 18.02M | 20.25M | 19.63M | 11.54M | 8.1M |
| EBIT | -102.09M | -219.72M | -214.78M | -187.06M | -247.01M | -220.27M | -203.77M | -146.41M |
| Net Interest Income | 8.12M | 5.94M | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M | -3.86M |
| Interest Income | 8.12M | 5.94M | 1.17M | 7.05M | 23.45M | 24.07M | 13.08M | -3.86M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -27.29M | 7.46M | -35.44M | 3.94M | 12.38M | 15.76M | -70.67M | -98.1M |
| Pretax Income | -129.38M▲ 0% | -204.47M▼ 58.0% | -250.22M▼ 22.4% | -183.12M▲ 26.8% | -234.63M▼ 28.1% | -342.99M▼ 46.2% | -274.45M▲ 20.0% | -246.41M▲ 0% |
| Pretax Margin % | -19692.09% | -2636.31% | -2349.47% | -216.24% | -180486.15% | -562285.25% | -762355.56% | -794858.06% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -129.38M▲ 0% | -204.47M▼ 58.0% | -250.22M▼ 22.4% | -183.12M▲ 26.8% | -234.63M▼ 28.1% | -342.99M▼ 46.2% | -274.45M▲ 20.0% | -246.41M▲ 0% |
| Net Margin % | -19692.09% | -2636.31% | -2349.47% | -216.24% | -180486.15% | -562285.25% | -762355.56% | -794858.06% |
| Net Income Growth % | - | -58.04% | -22.37% | 26.82% | -28.13% | -46.18% | 19.98% | 26.34% |
| Net Income (Continuing) | -129.38M | -204.47M | -250.22M | -183.12M | -234.63M | -342.99M | -274.45M | -246.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.53▲ 0% | -0.84▼ 59.4% | -1.03▼ 22.2% | -0.74▲ 28.1% | -0.93▼ 26.1% | -1.31▼ 40.1% | -16.06▼ 1126.0% | -11.26▲ 0% |
| EPS Growth % | - | -59.42% | -22.16% | 28.1% | -26.14% | -40.14% | -1125.95% | -919.69% |
| EPS (Basic) | -0.53 | -0.84 | -1.03 | -0.74 | -0.93 | -1.31 | -16.06 | - |
| Diluted Shares Outstanding | 12.33M | 12.33M | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M | 21.88M |
| Basic Shares Outstanding | 12.33M | 12.33M | 12.14M | 12.35M | 12.55M | 13.07M | 17.09M | 21.88M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
LYEL Balance Sheet
Lyell Immunopharma, Inc. (LYEL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 440.26M | 617.55M | 626.29M | 651.29M | 554.69M | 379.59M | 260.94M | 267.3M |
| Cash & Short-Term Investments | 436.05M | 612.62M | 614.79M | 640.15M | 546.22M | 370.53M | 247.22M | 254.02M |
| Cash Only | 96.67M | 140.41M | 293.83M | 123.55M | 145.65M | 105.6M | 60.18M | 90.77M |
| Short-Term Investments | 339.38M | 472.21M | 320.97M | 516.6M | 400.58M | 264.93M | 187.04M | 163.25M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 11.14M | 8.46M | 9.07M | 13.72M | 13.28M |
| Total Non-Current Assets | 115.37M | 290.73M | 501.12M | 286.27M | 195.34M | 111.27M | 79.11M | 83.32M |
| Property, Plant & Equipment | 43.7M | 124.06M | 166.64M | 166.26M | 142.32M | 72.94M | 53.64M | 50.55M |
| Fixed Asset Turnover | 0.02x | 0.06x | 0.06x | 0.51x | 0.00x | 0.00x | 0.00x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 68.98M | 163.44M | 330.53M | 115.04M | 48.51M | 32.01M | 19M | 96.06M |
| Other Non-Current Assets | 2.68M | 3.23M | 3.95M | 4.96M | 4.52M | 6.31M | 6.47M | 28.49M |
| Total Assets | 555.63M▲ 0% | 908.28M▲ 63.5% | 1.13B▲ 24.1% | 937.56M▼ 16.8% | 750.03M▼ 20.0% | 490.86M▼ 34.6% | 340.05M▼ 30.7% | 350.63M▲ 0% |
| Asset Turnover | 0.00x | 0.01x | 0.01x | 0.09x | 0.00x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | - | 63.47% | 24.13% | -16.84% | -20% | -34.55% | -30.72% | -124.33% |
| Total Current Liabilities | 22.05M | 49.28M | 46.74M | 37.03M | 34.52M | 53.79M | 49.41M | 36.95M |
| Accounts Payable | 2.84M | 9.4M | 3.21M | 3.92M | 4.82M | 5.37M | 2.89M | 5.47M |
| Days Payables Outstanding | - | - | - | - | - | - | 91.51 | 544.68 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 4.51M | 6.09M | 4.99M | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 10.58M | 15.33M | 28.25M | 22.16M | 8.79M | 22.72M | 46.52M | 31.48M |
| Current Ratio | 19.97x | 12.53x | 13.40x | 17.59x | 16.07x | 7.06x | 5.28x | 5.28x |
| Quick Ratio | 19.97x | 12.53x | 13.40x | 17.59x | 16.07x | 7.06x | 5.28x | 5.28x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 125.53M | 140.56M | 150.88M | 67.28M | 60.56M | 54.25M | 42.44M | 40.01M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39.49M |
| Capital Lease Obligations | 27.13M | 50.96M | 66.65M | 63.17M | 56.89M | 50.99M | 41.92M | 132.8M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 532K | 4.57M | 4.11M | 3.66M | 3.25M | 517K | 6.75M |
| Total Liabilities | 147.58M | 189.84M | 197.62M | 104.31M | 95.08M | 108.03M | 91.85M | 76.96M |
| Total Debt | 27.47M | 54.57M | 67.82M | 67.7M | 63.17M | 58.97M | 41.92M | 39.49M |
| Net Debt | -69.2M | -85.83M | -226.01M | -55.85M | -82.48M | -46.63M | -18.26M | -51.28M |
| Debt / Equity | 0.07x | 0.08x | 0.07x | 0.08x | 0.10x | 0.15x | 0.17x | 0.17x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.28x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.37x |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | 408.06M▲ 0% | 718.44M▲ 76.1% | 929.79M▲ 29.4% | 833.25M▼ 10.4% | 654.95M▼ 21.4% | 382.82M▼ 41.5% | 248.2M▼ 35.2% | 273.67M▲ 0% |
| Equity Growth % | - | 76.06% | 29.42% | -10.38% | -21.4% | -41.55% | -35.17% | -139.06% |
| Book Value per Share | 33.10 | 58.27 | 76.61 | 67.45 | 52.19 | 29.28 | 14.52 | 12.51 |
| Total Shareholders' Equity | 408.06M | 718.44M | 929.79M | 833.25M | 654.95M | 382.82M | 248.2M | 273.67M |
| Common Stock | 1K | 2K | 24K | 25K | 25K | 29K | 2K | 2K |
| Retained Earnings | -129.67M | -334.14M | -584.36M | -767.48M | -1B | -1.35B | -1.62B | -1.64B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 454K | 256K | -1.62M | -7.6M | -94K | 291K | 242K | -9K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LYEL Cash Flow Statement
Lyell Immunopharma, Inc. (LYEL) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 39.47M | -160.87M | -126.25M | -169.56M | -163.69M | -162.39M | -150.02M | -150.02M |
| Operating CF Margin % | 6008.22% | -2074.19% | -1185.44% | -200.22% | -125918.46% | -266219.67% | -416733.33% | - |
| Operating CF Growth % | - | -507.54% | 21.52% | -34.3% | 3.46% | 0.79% | 7.62% | 89.37% |
| Net Income | -129.38M | -204.47M | -250.22M | -183.12M | -234.63M | -342.99M | -274.45M | -246.41M |
| Depreciation & Amortization | 1.26M | 4.29M | 13.62M | 16.47M | 20.25M | 19.63M | 11.54M | 13M |
| Stock-Based Compensation | 15.73M | 33.26M | 62.2M | 0 | 47.08M | 33.14M | 41.83M | 40.1M |
| Deferred Taxes | -1.52M | 0 | 39.51M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 42.57M | 6.38M | 4.62M | 79.11M | 183K | 130.94M | 80.95M | 59.85M |
| Working Capital Changes | 110.81M | -336K | 4.01M | -82.02M | 3.42M | -3.12M | -9.89M | -340K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 1.71M | -278K | 91K | 667K | 1.46M | -3.23M | -2.34M | 1.7M |
| Cash from Investing | -422.43M | -273.52M | -121.57M | -11.54M | 184.05M | 122.42M | 54.1M | 2.01M |
| Capital Expenditures | -16.05M | -51.48M | -65.5M | -24.28M | -2.69M | -464K | -780K | -685K |
| CapEx % of Revenue | 2442.47% | 663.76% | 615.06% | 28.67% | 2066.15% | 760.66% | 2166.67% | - |
| Acquisitions | 0 | 0 | 673.47M | 0 | 0 | -31.35M | -41.2M | -40.93M |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -610.84M | 0 | -673.47M | 0 | 0 | 0 | -18.9M | -4.69M |
| Cash from Financing | 351.16M | 476.79M | 401.24M | 10.63M | 1.74M | 1.33M | 50.41M | 102.13M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 351.16M | 476.42M | 391.8M | 11.1M | 2.2M | 1.4M | 50.41M | 50.41M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -185K | -11.81M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 373K | 9.44M | -461K | -457K | -76K | -1K | 51.72M |
| Net Change in Cash | -31.8M▲ 0% | 42.4M▲ 233.3% | 153.42M▲ 261.8% | -170.27M▼ 211.0% | 22.09M▲ 113.0% | -38.64M▼ 274.9% | -45.52M▼ 17.8% | -29.66M▲ 0% |
| Free Cash Flow | 23.43M▲ 0% | -212.35M▼ 1006.5% | -191.75M▲ 9.7% | -193.83M▼ 1.1% | -166.38M▲ 14.2% | -162.86M▲ 2.1% | -150.8M▲ 7.4% | -163.06M▲ 0% |
| FCF Margin % | 3565.75% | -2737.94% | -1800.5% | -228.89% | -127984.62% | -266980.33% | -418900% | -525993.55% |
| FCF Growth % | - | -1006.45% | 9.7% | -1.08% | 14.16% | 2.12% | 7.4% | 7.25% |
| FCF per Share | 1.90 | -17.22 | -15.80 | -15.69 | -13.26 | -12.46 | -8.82 | -8.82 |
| FCF Conversion (FCF/Net Income) | -0.31x | 0.79x | 0.50x | 0.93x | 0.70x | 0.47x | 0.55x | 0.66x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LYEL Key Ratios
Lyell Immunopharma, Inc. (LYEL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -36.3% | -30.36% | -20.77% | -31.53% | -66.1% | -86.98% | -85.71% |
| Return on Invested Capital (ROIC) | -32.72% | -24.11% | -18.94% | -27.45% | -59.22% | -53.99% | -53.99% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | -31952.78% | -37129.03% |
| Net Margin | -2636.31% | -2349.47% | -216.24% | -180486.15% | -562285.25% | -762355.56% | -794858.06% |
| Debt / Equity | 0.08x | 0.07x | 0.08x | 0.10x | 0.15x | 0.17x | 0.17x |
| FCF Conversion | 0.79x | 0.50x | 0.93x | 0.70x | 0.47x | 0.55x | 0.66x |
| Revenue Growth | 1080.52% | 37.31% | 695.15% | -99.85% | -53.08% | -40.98% | -52.31% |
LYEL SEC Filings & Documents
Lyell Immunopharma, Inc. (LYEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
LYEL Frequently Asked Questions
Lyell Immunopharma, Inc. (LYEL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lyell Immunopharma, Inc. (LYEL) reported $0.0M in revenue for fiscal year 2025. This represents a 95% decrease from $0.7M in 2019.
Lyell Immunopharma, Inc. (LYEL) saw revenue decline by 41.0% over the past year.
Lyell Immunopharma, Inc. (LYEL) reported a net loss of $246.4M for fiscal year 2025.
Dividend & Returns
Lyell Immunopharma, Inc. (LYEL) has a return on equity (ROE) of -87.0%. Negative ROE indicates the company is unprofitable.
Lyell Immunopharma, Inc. (LYEL) had negative free cash flow of $163.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More LYEL
Lyell Immunopharma, Inc. (LYEL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates